Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07222293

Assessment of AI Program 'DRISTi' as a Screening Tool

A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in the outcomes thus proving DRISTi is an effective DR diagnosis tool.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

New Century Ophthalmology - Oxford, Oxford, North Carolina, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to sign and date the informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Age (≥)21 years of age or older
  • Diagnosed with diabetes mellitus as per criteria established by the World Health Organization (WHO) or the American Diabetes Association (ADA)
  • Hemoglobin A1c (HbA1c) ≥ 6.5%
  • Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L)
  • Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)

Exclusion criteria

  • Persistent visual impairment in one or both eyes;
  • History of macular edema or retinal vascular (vein or artery) occlusion;
  • History of ocular injections, laser treatment of the retina, or intraocular surgery other than cataract surgery without complications;
  • Subject is contraindicated for fundus photography (for example, has light sensitivity);
  • Subject has contraindications for mydriatic medications or is unwilling or unable to dilate;
  • Subject is currently enrolled in an interventional study of an investigational device or drug for the same condition; or
  • Subject has a condition or is in a situation which in the opinion of the Investigator, might confound study results, may interfere significantly with the subject's participation in the study, or may result in ungradable clinical reference standard photographs
  • Subject falls into one of the below categories:
  • Adults unable to consent (individuals w/ impaired decision-making capacity)
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners

Treatment and study plan

Fundus Image Grading

Diagnostic Test

The image is graded by a fully automated AI device

Primary outcomes

  1. Accuracy of AI Grade

    Time frame: From time of arrival to completion of diagnostic tests, up to 8 hours

    AI generated image grades are directly compared to a Human generated image grade

Study contacts

Contact information is provided by the study sponsor or research team.

Adriana Valencia, Site Coordinator Raleigh

CONTACT

[email protected]

9192347406

Jeanne Champion, Primary Site Coordinator Oxford

CONTACT

[email protected]

9192347003

Sponsors and collaborators

Lead sponsor

Artelus AI

Industry

Registry information

Official study title

Assessment of 'DRISTi' as an Automated Diabetic Retinopathy Screening Tool in Diabetic Populations

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 29, 2025
Registry last updated
Dec 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.